GlassScriptPhysician profile
Adnan A Khan
NPI 1083861249
$6,740.40
in general payments reported to CMS, 2019-2025
24 companies · $1,720 in 2025
The $1,720 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,825 · 2020: $221 · 2021: $51.41 · 2022: $285 · 2023: $250 · 2024: $387 · 2025: $1,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,357.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $2,278.97 | 2019 | |
| Medtronic, INC. | $1,235.73 | 2024-2025 | Intellis Adaptivestim, Inceptiv, Primeadvanced Surescan |
| Boston Scientific Corporation | $801.67 | 2019-2023 | |
| Medtronic USA, INC. | $646.89 | 2019 | |
| Vertiflex, INC. | $388.13 | 2019 | |
| Globus Medical, INC. | $342.87 | 2025 | Senza |
| Spinal Simplicity, LLC | $225.96 | 2025 | Ha Minuteman G3-R |
| Nalu Medical, INC. | $157.68 | 2024-2025 | Nalu Neurostimulation System |
| Painteq LLC | $130.15 | 2023-2024 | Painteq |
| Abbott Laboratories | $115.02 | 2019-2023 | Proclaim |
| Insmed, INC. | $99.00 | 2019 | |
| Stryker Corporation | $67.41 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.19 | 2019 | |
| Spr Therapeutics, INC | $36.67 | 2025 | Sprint Pns System |
| Genesys Orthopedics Systems, L.L.C. | $23.24 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $23.08 | 2021 | |
| Lundbeck LLC | $16.49 | 2021 | |
| Scilex Pharmaceuticals INC. | $14.76 | 2019 | |
| Pfizer INC. | $13.89 | 2019 | |
| Forte Bio-Pharma LLC | $13.38 | 2020 | |
| Sunovion Pharmaceuticals INC. | $13.31 | 2019 | |
| Allergan, INC. | $12.58 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.74 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adnan Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.